[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@TTRAmyloid Avatar @TTRAmyloid Not Odd

Not Odd posts on X about $ions, $arwr, $gral, $cytk the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XXXX% finance XXXX% cryptocurrencies XXXX%

Social topic influence $ions #9, $arwr #23, $gral 7.14%, $cytk #7, $srpt #53, $rprx 4.76%, $exas 4.76%, $xene 2.38%, money 2.38%, $rytm XXXX%

Top accounts mentioned or mentioned by @biohazard3737 @fluoxefuckboy @drmakaryfda @betswrites @crisprtx @persimmonti @statnews @bioinvestor24 @avidresearch @ericschmidt151 @yaronwerber @samfazeli8 @tlorriman @crydevilcrypto @polymarket @polymarkettrade @rickygervais @chemlord3 @bigchodu @craigster771

Top assets mentioned Ionis Pharmaceuticals, Inc. Common Stock (IONS) Arrowhead Research Corporation (ARWR) GRAIL, Inc. Common Stock (GRAL) Cytokinetics Inc. (CYTK) Sarepta Therapeutics, Inc. (SRPT) Royalty Pharma plc Class A Ordinary Shares (RPRX) Exact Sciences Corp (EXAS) Xenon Pharmaceuticals Inc (XENE) Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Novartis AG (NVS) uniQure N.V. (QURE) Texas Pacific Land, Corp. (TPL) Illumina, Inc. (ILMN) Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Bitcoin Incognito (XBI) Agios Pharmaceuticals, Inc. (AGIO) psa10 coin (GRAIL)

Top Social Posts

Top posts by engagements in the last XX hours

"$xene nav1.7 program is interesting. But stop wasting money on depression and bipolar theyre likely to fail the phase X looks so bad. Stop wasting capital on psych go all out pain now. Cant invest until they fail psych"
X Link 2025-10-14T13:47Z 1387 followers, 1392 engagements

"Why $rytm only down X% with pdufa extension and $cytk was down 20%"
X Link 2025-11-07T13:49Z 1387 followers, 1317 engagements

"Robert Blum for biotech executive of the year for not selling $cytk to $nvs"
X Link 2025-11-11T15:36Z 1387 followers, 3758 engagements

"Once $capr has positive P3 controlled data then its no longer crapicor. I think approval is a lock. I change my mind when information change. I had to change my mind about $srpt when their trials turned up negative. Now I have to do the same with $capr"
X Link 2025-12-04T16:51Z 1387 followers, 4126 engagements

"FDA reviewers were against approving $srpt therapies including eteplirsen they were pressured to approve. The FDA reviewers now have the backing of management to not approve questionable therapies. I dont think Prasad is inserting himself into every decision like the $qure bulls are saying"
X Link 2025-12-05T17:36Z 1387 followers, 3919 engagements

"$tpl oil royalty worth 45x earnings $rprx drug royalty thats growing XX% annual worth 8x earnings"
X Link 2025-09-18T18:13Z 1384 followers, 1514 engagements

"I suspect $arwr is working on a deal to give 1/3 of plozasiran revenue to $ions. Thats why they priced their drug at 3x what $ions is thinking about for shtg. From the conciliatory tone of the arow conference better for two players to grow the market than one I think its whats happening behind the scenes"
X Link 2025-11-19T14:24Z 1384 followers, 2816 engagements

"$arwr has no choice but give 1/3 revenue to $ions. Either make a deal with $ions or risk losing in court and never come to the market"
X Link 2025-11-19T14:40Z 1384 followers, XXX engagements

"$gral is in a investor desert. Tech investor dont touch it because its not AI software or internet biotech funds wont touch it because they focus on therapeutics. Generalist wont touch it because its life science. Only bio fund with $gral position is baker brothers"
X Link 2025-11-20T14:31Z 1382 followers, XXX engagements

"$ions going up $arwr going down. Something is fishy about arwr pricing the drug at $60k"
X Link 2025-11-20T14:37Z 1384 followers, 1713 engagements

"He gave an example of a company that went up 4x from trough valuation trading at 1bil mcap now has a 1-2 billion drug so should be worth 4-8 billion. That company is $stok"
X Link 2025-11-24T13:05Z 1382 followers, 1670 engagements

"$gral is so far ahead of everyone else there is ZERO competition. Number X be able to have tissue of origin and then run a 100k patient trial"
X Link 2025-12-05T18:14Z 1383 followers, XXX engagements

"Cancer testing requires high trust. Galleri would be the most trusted mced and take most of the market. by the time any competitor test get on the market the moat would be so deep and wide they wont be able to give the test away. $gral"
X Link 2025-12-05T18:18Z 1382 followers, XXX engagements

"In biotech insider buying is not a positive signal. Its usually a signal that its trash and insiders are just trying to send a positive signal. $bhvn"
X Link 2025-11-17T14:28Z 1386 followers, 4487 engagements

"Time for $ions to get injunction against the copy cat $arwr"
X Link 2025-11-18T16:23Z 1385 followers, XXX engagements

"$agio sold voranigo and their oncology program for X billion voranigo is now generating over 1b in sales per year. They could have done a royalty deal with $rprx. Ultimate cut your flowers to water the weed. Really bad management"
X Link 2025-11-19T14:09Z 1385 followers, 2210 engagements

"$exas with crappy cologuard that is pretty useless is worth 15b. $grail Galleri works and in a MUCH bigger tam only XXX b MC XXX EV was negative XXX m EV when I bought it last year lol. You cant get a valuation gap bigger than this"
X Link 2025-11-19T19:31Z 1386 followers, 1018 engagements

"Why do bears not like $fulc data"
X Link 2025-12-06T23:46Z 1387 followers, 1478 engagements